TRDA
NASDAQ · Biotechnology
Entrada Therapeutics Inc
$6.78
-0.07 (-1.02%)
Open$6.78
Previous Close$6.85
Day High$6.80
Day Low$6.01
52W High$16.45
52W Low$4.93
Volume—
Avg Volume688.7K
Market Cap622.29M
P/E Ratio—
EPS$-3.47
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+166.1% upside
Current
$6.78
$6.78
Target
$18.04
$18.04
$12.20
$18.04 avg
$27.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 56.40M | 42.90M | 41.05M |
| Net Income | -318,912,194 | 8.98M | 10.98M |
| Profit Margin | -565.5% | 20.9% | 26.8% |
| EBITDA | -341,215,672 | 15.57M | 16.71M |
| Free Cash Flow | — | 11.03M | 8.57M |
| Rev Growth | — | +8.9% | +15.8% |
| Debt/Equity | — | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |